These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24795813)

  • 1. Targeting RANKL in metastasis.
    Dougall WC; Holen I; González Suárez E
    Bonekey Rep; 2014; 3():519. PubMed ID: 24795813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab: A comprehensive review.
    Narayanan P
    South Asian J Cancer; 2013 Oct; 2(4):272-7. PubMed ID: 24455656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of osteoclastic activity in prostate cancer skeletal metastases.
    Keller ET
    Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANK and RANK ligand expression in primary human osteosarcoma.
    Branstetter D; Rohrbach K; Huang LY; Soriano R; Tometsko M; Blake M; Jacob AP; Dougall WC
    J Bone Oncol; 2015 Sep; 4(3):59-68. PubMed ID: 27556008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
    Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
    Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RANKL/RANK in primary and secondary breast cancer.
    Yoneda T; Tanaka S; Hata K
    World J Orthop; 2013 Oct; 4(4):178-85. PubMed ID: 24147253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RANK expression on breast cancer cells promotes skeletal metastasis.
    Blake ML; Tometsko M; Miller R; Jones JC; Dougall WC
    Clin Exp Metastasis; 2014 Feb; 31(2):233-45. PubMed ID: 24272640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
    Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
    Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
    Brown-Glaberman U; Stopeck AT
    Biologics; 2012; 6():89-99. PubMed ID: 22532777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
    Lipton A; Goessl C
    Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab: a new option in the treatment of bone metastases from urological cancers.
    Yuasa T; Yamamoto S; Urakami S; Fukui I; Yonese J
    Onco Targets Ther; 2012; 5():221-9. PubMed ID: 23055747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
    Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
    J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of RANKL-Targeted Therapy in Immunity and Cancer.
    Cheng ML; Fong L
    Front Oncol; 2014 Jan; 3():329. PubMed ID: 24432249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL inhibition in the treatment of bone metastases.
    Lipton A; Jun S
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.
    Terpos E; Efstathiou E; Christoulas D; Roussou M; Katodritou E; Dimopoulos MA
    Expert Opin Biol Ther; 2009 Apr; 9(4):465-79. PubMed ID: 19344283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.